ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 39.7% YoY; 6% QoQ growth. Strongest Q1 in 4 years. |
|---|---|
| Margins | Sequential EBITDA margin at 16.9%; targeting 19-20% by Q4 FY27. |
| Order book | Robust; 105 active clients. Large tectonic deals ramping up. |
| Demand visibility | Positive; clients excited by AI, though enterprise adoption remains measured. |
| Management confidence | Confident, shifting from optimism to conviction regarding GenAI and scale. |
Growth
Revenue grew 39.7% YoY; 6% QoQ. Growth is high-quality, driven by accounts beyond top 20.
Outlook
EBITDA margins expected to return to 19-20% by Q4 FY27 as revenue scales.
Risks
Margins are under pressure from upfront tectonic deal costs and workforce transformation expenses.
Last quarter's promises, checked
Delivered
- Revenue ₹3,500cr+ FY26 → ₹35,105M (= BEAT)
- Q4 Revenue ₹1,000cr+ → ₹10,000M (= BEAT)
- Active customers 73 to 91 → 105 (= BEAT)
Partly delivered
- DSO 63 days → 60s to 70s guidance (= PARTIAL)
Missed
- EBITDA margin 19-20% → 16.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹623.85
- Market cap
- ₹15,030 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 54.5×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Earnings Call Transcript: Key Takeaways
Strong top-line growth driven by pharma digital transformation, but near-term margins are compressed by annual wage hikes and mutual fund mark-downs.
Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 11,223M (+39.5% YoY, +5.6% QoQ), EBITDA margin 16.7%, PAT INR 1,123M (+10% YoY). BioPharm integration ahead of plan.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY
Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹112.3 Cr · +10.0% YoY